Actively Recruiting
Mesopancreatic Excision for Pancreatic Duct Adenocarcinoma.
Led by Minia University · Updated on 2025-08-29
100
Participants Needed
1
Research Sites
160 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with high rates of local recurrence and distant metastasis. Recent evidence suggests that mesopancreatic excision (TMpE) may improve R0 resection rates, reduce local recurrence, and enhance overall survival compared to standard pancreatoduodenectomy. However, most existing studies are retrospective with heterogeneous patient populations and surgical techniques. This prospective study aims to evaluate the impact of mesopancreatic excision, a surgical technique involving the meticulous removal of retroperitoneal tissue surrounding major peripancreatic vessels, on local disease control and overall survival in patients undergoing pancreaticoduodenectomy for resectable PDAC. The study will also assess R0 resection rates, disease-free survival, recurrence patterns and perioperative outcomes.
CONDITIONS
Official Title
Mesopancreatic Excision for Pancreatic Duct Adenocarcinoma.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Scheduled to undergo pancreaticoduodenectomy with planned mesopancreatic excision
- Histologically confirmed pancreatic ductal adenocarcinoma of the pancreatic head
- Resectable disease according to NCCN guidelines (no distant metastases, no arterial involvement greater than 180 degrees, reconstructable venous involvement)
- ECOG performance status between 0 and 2
- Adequate organ function (bilirubin less than 1.5 times upper limit of normal, creatinine clearance over 50 mL/min)
- Provided informed consent
You will not qualify if you...
- Borderline resectable or unresectable pancreatic ductal adenocarcinoma
- Presence of distant metastases
- Periampullary tumors other than pancreatic adenocarcinoma
- Prior neoadjuvant chemotherapy or radiotherapy
- Active second malignancy
- Severe health problems preventing surgery (e.g., uncontrolled heart disease)
- Pregnancy or breastfeeding
- Previous radiotherapy to the abdomen
- Unable or unwilling to give informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Liver and GIT hospital , Minia University
Minya, Minya Governorate, Egypt, 61519
Actively Recruiting
Research Team
S
Saleh K Saleh, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here